Breast Cancer Clinical Trial
Official title:
Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction
Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, the investigators created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection. Safety indicator, cosmetic outcome and autologous compatibility were evaluated.
3D image reconstruction and printing Magnetic model images data were firstly produced by
Siemens Trio Tim 3. 0 T MRI. The relative scanning parameters were adjusted as follows: layer
thickness 0.9mm; pixel pitch 0.625 mm. In general, the thicker the layer thickness and pixel
pitch, the better resolution and the more similar reconstructed model the investigators will
get. The MRI data were then imported into Mimics 17.0® [Materialise, Leuven, Belgium] for 3D
reconstruction of the targeted area. In this software, the investigators can adjust threshold
value to acclimatize to segment tumor area. After that, 3D models were calculated and output
as .stl files. According to the requirements of surgical planning, the scope of tumor
resection was created after 2 cm expansion of the tumor area, that is, the filling scope of
the implant. Next, the investigators designed the personalized porous degradable scaffold. In
order to guarantee no significant differences and deformation of the implanted scaffold, the
investigators used the contour of tumor resection as the boundary of the scaffold, with
flexible porous structure as the units of the scaffold. Boolean operation can help to achieve
this target. Finally, the printing of the personalized porous biodegradable scaffold was
carried out. Biologically active material PCL was selected and the deformation and
degradation time were set for 2 years by adjusting the molecular weight of PCL.
Theoretically, PCL with the molecular weight above 65,000 can stably exist for 2 years in
vivo, and then it will gradually degrade into H2O and CO2.The PCL material was put into the
3D printer, which was developed by the State key laboratory for mechanical manufacturing
systems engineering of Xi'an Jiaotong university. The personalized porous biodegradable
scaffold was completed after printing and removing supports.
Procedure In this study,the investigators produced the bio-implant at least 10 days before
surgery. Before surgery, the printed bio-implant has been prepared and obtained full
sterilization. Simply, under general anaesthesia, lumpectomy and sentinel-lymph-node biopsy
was performed firstly, followed by 3D-printing scaffold transplantation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |